Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyModa Health romiplostim Prior Auth Coverage | Open…
    Ask Trek AI about this page
    CurrentModa HealthPolicy IC-0089

    Nplate (romiplostim) coverage and authorization

    Customize your policy alerts

    Sign up for Moda Health Policy IC-0089 alerts

    Get alerted when Policy IC-0089 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy IC-0089 defines prior authorization, dosing limits, indications, renewal criteria, and billing/coding rules for romiplostim (Nplate) for Moda Health members.

    Policy Summary
    PayerModa Health
    PolicyNplate (romiplostim) coverage and authorization
    Policy CodePolicy IC-0089
    Change TypeNo material changes
    Effective DateFeb 3, 2026
    Last ReviewFeb 3, 2026
    Next Review DateFeb 3, 2026
    Key ActionObtain prior authorization for romiplostim with documentation of current platelet value and prior therapies; initial approvals valid for 90 days and may be renewed when criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    90 daysinitial prior authorization validity
    1250max weekly HCPCS units (ITP/CIT/ICI)
    >=50ITP renewal platelet threshold
    J2802HCPCS code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3
    NDCs listed
    ~20references cited

    Coverage Criteria for Romiplostim (Nplate)

    inv-01: Universal Criteria

    Covered when ALL of the following universal criteria are met

    Universal criteria: Patient is not on concurrent treatment with any other thrombopoietin receptor agonist or mimetic or fostamatinib; AND romiplostim therapy will be used to decrease the risk of bleeding from thrombocytopenia (i.e., will NOT be used to normalize platelet counts); AND laboratory platelet values are current (drawn within the previous 28 days); NOTE: does not apply to patients receiving treatment for Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS).

    inv-02: ITP Initial Therapy

    Immune (idiopathic) Thrombocytopenia (ITP) — initial approval

    ITP initial: Patient is at increased risk for bleeding as indicated by platelet count <30 x10^9/L; AND patient has acute ITP; AND patient is at least 18 years of age; AND patient has previously failed corticosteroids OR immunoglobulins OR splenectomy; OR patient has chronic ITP (>=6 months or meets corticosteroid requirement), is at least 1 year of age, and has previously failed corticosteroids (no response to >=3-month trial or corticosteroid‑dependent) OR immunoglobulins OR splenectomy.platelets <30 x10^9/L (acute) or chronic >=6 months

    inv-03: HS-ARS Initial Therapy

    Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS) — initial approval

    HS-ARS initial: Patient has suspected or confirmed exposure to radiation levels greater than 2 gray (Gy).radiation exposure >2 Gy

    inv-04: CIT Initial Therapy

    Chemotherapy-Induced Thrombocytopenia (CIT) — initial approval

    CIT initial: Patient is at least 18 years of age; AND patient has a platelet count <100 x10^9/L for at least 3–4 weeks after the last chemotherapy administration and/or after delays in chemotherapy initiation related to thrombocytopenia.platelets <100 x10^9/L for >=3-4 weeks

    inv-05: MDS Initial Therapy

    Myelodysplastic Syndromes (MDS) — initial approval

    MDS initial: Patient is at least 18 years of age; AND patient has lower‑risk disease (IPSS‑R Very Low, Low, or Intermediate); AND patient has severe or refractory thrombocytopenia (platelet count <50 x10^9/L); AND patient progressed, had no response to, or relapsed after hypomethylating agents or immunosuppressive therapy.platelets <50 x10^9/L

    inv-06: Immune Checkpoint Inhibitor-Related Thrombocytopenia

    Management of Immune Checkpoint Inhibitor‑Related Thrombocytopenia — initial approval

    ICI‑toxicity initial: Patient is at least 18 years of age; AND patient has been receiving an immune checkpoint inhibitor; AND patient has thrombocytopenia related to immunotherapy; AND romiplostim is used as additional therapy for grade 3 or 4 disease if there is no response to corticosteroids after 1–2 weeks.

    Compendia‑recommended indication.

    inv-07: Renewal Criteria

    Covered when ALL of the following are met

    Renewal general: Patient continues to meet the universal and indication‑specific criteria; AND duration of authorization has not been exceeded; AND there is absence of unacceptable toxicity from romiplostim (examples include thrombotic/thromboembolic complications, risk of progression of MDS to AML, loss of response/neutralizing antibodies).
    ITP renewal response: Disease response: achievement and maintenance of platelet count >=50 x10^9/L (not to exceed 400 x10^9/L) as necessary to reduce bleeding risk.>=50 x10^9/L
    CIT renewal response: Patient continues to receive chemotherapy; AND disease response: achievement and maintenance of platelet count >=100 x10^9/L (not to exceed 400 x10^9/L).>=100 x10^9/L

    Romiplostim is not intended to be used to normalize platelet counts. Coverage requires that the documented intent of therapy is to decrease the risk of bleeding from thrombocytopenia rather than to achieve or maintain normal platelet values. Requests that indicate an aim to normalize platelets are not consistent with this policy requirement.

    When Medicare members are involved, applicable Medicare rules must be followed. National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) — and any Local Coverage Articles (LCAs) used for claims payment or benefit clarification — may apply and must be complied with where relevant. This policy’s criteria are intended for non‑Medicare coverage determinations and do not replace CMS requirements.

    Prior authorization renewals may be denied or not renewed if the member develops unacceptable toxicitythrombotic or thromboembolic complications, evidence suggesting progression of myelodysplastic syndromes to acute myelogenous leukemia, or loss of response/neutralizing antibodies to romiplostim. Documentation of ongoing safety and absence of these issues is required for continued coverage.

    Billing, Codes, and Quantity Limits

    HCPCS CodeHCPCS
    J2802Injection, romiplostim, 1 microgram; 1 billable unit = 1 mcg
    NDCsNDC
    55513-0223-xxNplate 125 mcg single-dose vial NDC
    55513-0221-xxNplate 250 mcg single-dose vial NDC
    55513-0222-xxNplate 500 mcg single-dose vial NDC
    Covered HCPCS CodesHCPCSCovered
    J2802Injection, romiplostim, 1 microgram; 1 billable unit = 1 mcg
    NDCsNDC
    55513-0223-xxNplate 125 mcg single-dose vial NDC
    55513-0221-xxNplate 250 mcg single-dose vial NDC
    55513-0222-xxNplate 500 mcg single-dose vial NDC
    Covered ICD-10 Diagnosis CodesICD-10Covered
    C93.10Chronic myelomonocytic leukemia not having achieved remission
    D46.0Refractory anemia without ring sideroblasts, so stated
    D46.1Refractory anemia with ring sideroblasts
    D46.20Refractory anemia with excess of blasts, unspecified
    D46.21Refractory anemia with excess of blasts 1
    D46.4Refractory anemia, unspecified
    D46.9Myelodysplastic syndrome, unspecified
    D46.ARefractory cytopenia with multilineage dysplasia
    D46.BRefractory cytopenia with multilineage dysplasia and ring sideroblasts
    D46.ZOther myelodysplastic syndromes
    1–10 of 19
    1/2
    Max HCPCS units per week — quantity limits by indication
    ITP, CIT, ICI‑related toxicities1250 billable HCPCS units per week
    Myelodysplastic syndromes (MDS)1000 billable HCPCS units per week
    Hematopoietic Syndrome of Acute Radiation Syndrome (HS‑ARS)1250 billable HCPCS units as a single (x1) dose

    Prior Authorization, Documentation, and Provider Requirements

    Prior Authorization

    Prior authorization required — initial 90 days; renew every 90 days when criteria met

    Prior authorization is required before initiating romiplostim. Initial approvals are provided for 90 days (3 months) and may be renewed every 90 days when the member continues to meet the universal and indication‑specific criteria; note that prior authorization validity for Management of Immune Checkpoint Inhibitor‑Related Toxicities and HS‑ARS may NOT be renewed.

    • Initial: prior authorization validity 3 months (90 days).
    • Renewal: may be renewed every 3 months (90 days) when criteria are met.
    • Exceptions: PA validity may NOT be renewed for Management of Immune Checkpoint Inhibitor‑Related Toxicities and HS‑ARS.
    Note

    PA considered due to drug cost (NQTL)

    Prior authorization is applied to romiplostim in part because the NQTL checklist identified drug cost as a factor to consider for PA.

    Background and Clinical Context

    Romiplostim (Nplate®) is a thrombopoietin receptor agonist that stimulates platelet production and is used to increase platelet counts to reduce bleeding risk in conditions such as immune (idiopathic) thrombocytopenia (ITP), chemotherapy‑induced thrombocytopenia (CIT), lower‑risk myelodysplastic syndromes (MDS), management of immune checkpoint inhibitor‑related thrombocytopenia, and hematopoietic syndrome of acute radiation syndrome (HS‑ARS). Coverage under this policy is provided for FDA‑approved and compendia‑recommended indications when the specific clinical and documentation criteria are met.

    Definitions and Referenced Guidance

    Universal Criteria — operational requirements
    No concurrent TPO‑RA or fostamatinibPatient must not be on concurrent treatment with any other thrombopoietin receptor agonist, mimetic, or fostamatinib.
    Intent to decrease bleeding risk (not normalize platelets)Romiplostim therapy must be used to decrease the risk of bleeding from thrombocytopenia and not to normalize platelet counts.
    Recent platelet lab requiredLaboratory platelet value must be current (drawn within the previous 28 days); NOTE: this requirement does not apply to HS‑ARS patients.
    Supporting compendia/guidelinesPolicy references NCCN Drugs & Biologics Compendium and NCCN Clinical Practice Guidelines in Oncology among other clinical references to support indications and rationale.
    NCCN Compendium / Guidelines — referenced compendia and guideline sources
    NCCN Drugs & Biologics Compendium

    Line of Therapy / Salvage Use

    inv-28: Salvage

    Salvage therapy criteria

    MDS salvage: Use in lower‑risk MDS after progression, lack of response, or relapse following hypomethylating agents or immunosuppressive therapy.
    Policy Summary
    PayerModa Health
    PolicyNplate (romiplostim) coverage and authorization
    Policy CodePolicy IC-0089
    Change TypeNo material changes
    Effective DateFeb 3, 2026
    Last ReviewFeb 3, 2026
    Next Review DateFeb 3, 2026
    Key ActionObtain prior authorization for romiplostim with documentation of current platelet value and prior therapies; initial approvals valid for 90 days and may be renewed when criteria are met.
    SourceLink
    On This Page
    Coverage Criteria for Romiplostim (Nplate)Billing, Codes, and Quantity LimitsPrior Authorization, Documentation, and Provider RequirementsBackground and Clinical ContextDefinitions and Referenced GuidanceLine of Therapy / Salvage Use
    MDS renewal response:
    Patient has not developed acute myeloid leukemia (note: romiplostim may increase immature white blood cells/peripheral blasts which is not indicative of AML); AND disease response as shown by an increase in platelet count compared to pretreatment baseline, reduction in bleeding events, or reduction in platelet transfusion requirements (not to exceed 450 x10^9/L).
    <=450 x10^9/L
  1. NQTL checklist: Cost of drug = Yes (Consider for PA).
  2. Documentation Required

    Document prerequisite therapies for ITP and MDS

    Provide documentation of prior therapies as applicable to the indication: for ITP, prior treatment with corticosteroids, immunoglobulins, or splenectomy (or chronic ITP meeting corticosteroid trial criteria) must be documented; for MDS, documentation of progression or lack of response after hypomethylating agents or immunosuppressive therapy is required.

    • ITP: prior failure of corticosteroids OR immunoglobulins OR splenectomy (or chronic ITP meeting corticosteroid requirement: no response to ≥3‑month trial or corticosteroid‑dependent).
    • MDS: progressed, no response to, or relapsed after hypomethylating agents or immunosuppressive therapy.
    Note

    Provider action highlight: intent and concurrent‑therapy restrictions

    Ensure intent of therapy is to decrease bleeding risk and not to normalize platelet counts; do not prescribe romiplostim concurrently with another TPO receptor agonist or fostamatinib.

    • Therapy must be used to decrease bleeding risk (will NOT be used to normalize platelet counts).
    • No concurrent treatment with any other thrombopoietin receptor agonist/mimetic or fostamatinib.
    Documentation Required

    Required clinical documentation — current platelet within 28 days and indication details

    Include a current platelet laboratory value drawn within the previous 28 days with PA requests and other indication‑specific documentation as applicable.

    • Current platelet count must be from a specimen drawn within the previous 28 days (note: does not apply to HS‑ARS).
    • Also provide documentation supporting the specific indication (e.g., timing after chemotherapy, risk category for MDS, corticosteroid trial results for ITP).
    Billing Rule

    Coding and drug identification — use HCPCS J2802; NDCs may be referenced

    Bill romiplostim using HCPCS code J2802 (Injection, romiplostim, 1 microgram); NDCs for the single‑dose vial strengths may be referenced on claims when applicable (55513‑0223‑xx, 55513‑0221‑xx, 55513‑0222‑xx).

    • HCPCS: J2802 — Injection, romiplostim, 1 microgram; 1 billable unit = 1 mcg.
    • NDCs (may be referenced): 55513‑0223‑xx (125 mcg), 55513‑0221‑xx (250 mcg), 55513‑0222‑xx (500 mcg).
    Denial Risk

    Denial/non‑renewal triggers — unacceptable toxicity, progression risk, loss of response

    Prior authorization may be denied or not renewed if the member experiences unacceptable toxicity (examples provided include thrombotic/thromboembolic complications), if there is risk of progression of MDS to AML, loss of response or presence of neutralizing antibodies, or if duration limits are exceeded.

    • Unacceptable toxicity examples: thrombotic/thromboembolic complications.
    • Other denial triggers: risk of progression of MDS to acute myelogenous leukemia (AML); loss of response to romiplostim/presence of neutralizing antibodies; duration limits exceeded.
    Step Therapy

    PA considered because drug cost identified as a factor in NQTL checklist

    Prior authorization consideration for romiplostim was influenced by cost according to the NQTL factor checklist; document that PA may be applied for utilization management because drug cost was marked 'Yes' on the checklist.

    • Appendix A NQTL checklist: Cost of drug = Yes, consider for PA.
    Referenced with permission for romiplostim (NCCN Compendium®).
    NCCN Clinical Practice Guidelines in OncologyNCCN guidelines (e.g., Hematopoietic Growth Factors) cited as supporting references.
    Package insert and clinical trialsNplate package insert (Amgen, Mar 2025) and multiple trials (e.g., Giagounidis 2014; Bussel, Kuter et al.) are listed in references supporting coverage rationale.